PHARMACEUTICAL PREPARATIONS
Vogenx Inc Common Stock
VOGX
Vogenx Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia, or PBH, and gastroparesis. The company's flagship product candidate, mizagliflozin, is an orally administered, minimally absorbed, small molecule drug candidate being developed for the treatment of post-bariatric hypoglycemia (PBH), gastroparesis and GIP-induced Cushing's Syndrome. It operates as a single reportable segment engaged in the discovery and development of treatments for serious metabolic and gastrointestinal diseases.
Open XNAS
Fundamentals
Key company ratios and reported financial statements.
Key ratios
No ratio data was found for VOGX.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.
| Line item | Q3 FY2026 Sep 30, 2026 |
|---|---|
| Revenue | $0 |
| Cost of revenue | $0 |
| Gross profit | $0 |
| Selling, general and administrative | $703.74K |
| Research and development | $1.08M |
| Total operating expenses | $1.78M |
| Operating income | -$1.78M |
| Interest expense | $0 |
| Income before taxes | -$4.91M |
| Income taxes | $0 |
| Net income | -$4.91M |
| Net income attributable to common shareholders | -$4.91M |
| EBITDA | -$1.78M |
| Basic earnings per share | -$0.47 |
| Diluted earnings per share | -$0.47 |
Recent news
Company coverage with links to the original publishers.
No recent company news found.
Dividends
Declared distributions and recorded event dates. Forecasts are not shown.
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.
No stock split records found.